CI Stock - Cigna Corporation

The Cigna Group (CI) has fundamentally reshaped its financial profile following the March 19, 2025, completion of the sale of its Medicare Advantage, Medicare Supplemental, and Part D businesses to Health Care Service Corp (HCSC). The revised 2026 guidance reflects a strategic pivot away from the high-volatility, government-funded Medicare segment toward the higher-margin, capital-light Evernorth Health Services division.

Strategic Divestiture and Revenue Normalization

The sale to HCSC, valued at approximately $3.7 billion, resulted in a significant reduction in the Cigna Healthcare segment's top-line revenue but served as a catalyst for earnings per share (EPS) accretion through aggressive capital redeployment.

• Revenue Impact: The divestiture contributed to an -11% decline in annual adjusted revenues for the Cigna Healthcare unit in 2025. However, consolidated 2026 revenue is projected to recover to approximately $280 billion, driven by organic growth in Evernorth.
• Capital Deployment: Cigna utilized the majority of the $3.3 billion in cash proceeds to fund share repurchases. In 2025 alone, the company repurchased 11.9 million shares for $3.6 billion, effectively offsetting the earnings "leakage" from the lost Medicare business.
• 2026 EPS Guidance: Management has established a floor for 2026 adjusted income from operations at $30.25 per share. This guidance accounts for the full-year absence of Medicare earnings while benefiting from a lower share count and improved segment mix.

Segment Profile: Evernorth vs. Cigna Healthcare

The 2026 outlook underscores a "services-led" growth model where Evernorth provides the bulk of the earnings power, while the Commercial insurance segment focuses on margin stability over membership volume.

• Evernorth Health Services: Projected to deliver at least $6.9 billion in adjusted pre-tax earnings in 2026. Growth is primarily fueled by Specialty Pharmacy services, which saw 14% revenue growth in late 2025.
• Cigna Healthcare (Commercial Core): Expected to contribute at least $4.5 billion in adjusted pre-tax earnings. By exiting Medicare, Cigna has lowered its consolidated Medical Care Ratio (MCR) target to a range of 83.7% to 84.7% for 2026, reflecting a more predictable cost profile in employer-sponsored plans compared to the rising utilization trends seen in Medicare Advantage.

Regulatory Risk Mitigation and Structural Shifts

The exit from Medicare Advantage significantly reduces Cigna’s exposure to annual CMS (Centers for Medicare & Medicaid Services) rate fluctuations and Star Rating volatility, which have pressured peers like UnitedHealth and Humana.

• FTC Settlement: In early 2026, Cigna reached a comprehensive settlement with the Federal Trade Commission (FTC) regarding its Pharmacy Benefit Manager (PBM) practices. While the settlement includes $7 billion in out-of-pocket relief for patients over 10 years, management indicated it does not alter the long-term "growth algorithm" or margin profile of the PBM business.
• Rebate-Free Model: To further reduce regulatory scrutiny, Cigna is transitioning toward a "rebate-free" pharmacy benefit model. This shift is expected to be margin-neutral in the long term but requires infrastructure investment in 2026, which is already baked into the $30.25 EPS guidance.

Risk Factors and Uncertainties

Despite the de-risking of the portfolio, several variables could impact the 2026 realization:

1. PBM Legislative Pressure: Ongoing federal and state-level legislative efforts to reform PBM transparency could still compress margins beyond current projections.
2. Commercial Pricing Discipline: As Cigna prioritizes margins over growth, it faces the risk of membership attrition if competitors price more aggressively in the employer-sponsored market.
3. Capital Allocation Timing: The timing of the remaining share repurchases is critical to achieving the $30.25 EPS floor, as any delay in execution could lead to a slight earnings miss relative to consensus.

To insulate The Cigna Group’s (CI) bottom line from intensifying federal Pharmacy Benefit Manager (PBM) reforms—specifically the Consolidated Appropriations Act of 2026 and the "delinking" of fees from list prices—Evernorth Health Services has executed a multi-year structural pivot. This strategy shifts the business model from a rebate-dependent architecture to a transparent, fee-for-service framework while simultaneously "pruning" high-regulation insurance segments.

1. Structural Pivot: The "Rebate-Free" PBM Model

In late 2025, Evernorth announced a fundamental overhaul of its Express Scripts business model to preemptively align with federal "delinking" mandates (which prohibit PBM compensation based on a percentage of drug list prices in Medicare Part D starting in 2028).

• Fee-Based Compensation: Evernorth is transitioning to a model where revenue is derived from flat administrative fees per member per prescription, rather than retained rebates or "spread pricing."
• Point-of-Sale Discounting: Negotiated savings are passed directly to consumers at the pharmacy counter. This model is expected to reduce out-of-pocket costs for brand-name drugs by an average of 30%.
• Implementation Timeline: The model will be live for all Cigna fully insured plans by 2027, with a target of 50% of all Evernorth clients transitioning by the end of 2028.

2. Operational Realignment: Ascent GPO Relocation

As part of a landmark February 2026 settlement with the Federal Trade Commission (FTC), Cigna is restructuring its Group Purchasing Organization (GPO) to address transparency concerns.

• Domestic Relocation: Evernorth is moving Ascent Health Services (its GPO) from Switzerland to the United States. This move subjects the entity to U.S. oversight and tax jurisdictions, neutralizing legislative arguments regarding "opaque" offshore rebate retention.
• Financial Impact: Management noted this relocation could increase the company’s effective tax rate by up to 1% if unmitigated, though they maintain this is manageable within their long-term growth algorithm.

3. Portfolio Pruning: Medicare Advantage Divestiture

To insulate the enterprise from the regulatory volatility of federal programs, Cigna completed the sale of its Medicare Advantage (MA) and Supplemental Benefits businesses to Health Care Service Corporation (HCSC) in 2025.

• Risk Mitigation: This divestiture removed Cigna from the direct line of fire regarding tightening CMS reimbursement rates and escalating Medical Care Ratios (MCR) in the MA segment.
• Capital Reallocation: The transaction allowed Cigna to reallocate capital toward Evernorth’s high-growth, lower-regulation specialty pharmacy and behavioral health segments.

4. Product Innovation: "Clearity" and Cost-Plus Pricing

Evernorth has introduced new "capital-light" service offerings that prioritize transparency over traditional insurance risk.

• Clearity by Cigna Healthcare: Launched in November 2025, this copay-only health plan eliminates deductibles and coinsurance, utilizing AI-driven tools to provide upfront, transparent pricing.
• Cost-Plus Pharmacy Reimbursement: Starting in 2026, Evernorth is implementing a reimbursement model for in-network pharmacies based on the actual acquisition cost of the drug plus a fixed dispensing fee and clinical service fee.

5. Financial Outlook & Margin Sustainability

Despite the structural shift away from traditional PBM economics, The Cigna Group has maintained its long-term financial targets.

• 2026 Guidance: The company projected 2026 adjusted EPS of at least $30.25 and consolidated adjusted revenues of approximately $280B.
• Margin Profile: Management stated that while the source of profit is evolving (shifting from rebates to service fees), the overall margin profile for the pharmacy benefit services business remains intact, supporting a long-term EPS growth target of 10% to 14%.

The Cigna Group (CI) is currently navigating a capital allocation pivot characterized by a "buyback-first" mentality, fueled by the divestiture of its Medicare Advantage business and robust cash flows from its Evernorth health services segment. As of February 2026, management’s strategy prioritizes the immediate, high-certainty internal rate of return (IRR) of share repurchases over the execution risk and regulatory hurdles associated with mega-mergers like the previously rumored Humana integration.

1. Capital Allocation & Buyback Execution

In 2025, Cigna executed a disciplined capital return strategy, repurchasing 11.9 million shares for approximately $3.6B. This follows a multi-year trajectory where the company has retired over 137 million shares since 2018, representing a cumulative investment of $35.46B.

For 2026, management has established an outlook that includes at least $30.25 in adjusted EPS, supported by a projected $9.0B in cash flow from operations. The company’s debt-to-capitalization ratio stood at 43.0% at year-end 2025, providing significant "dry powder" for continued repurchases or opportunistic M&A.

2. Valuation Multiples vs. Implied Buyback IRR

The economic rationale for Cigna’s aggressive buyback program is rooted in the spread between its current earnings yield and its long-term growth algorithm.

• Current Valuation: As of mid-February 2026, Cigna trades at a forward P/E multiple of approximately 9.1x to 9.8x. This is significantly lower than its five-year historical average of ~11x to 13x and represents a steep discount compared to diversified peers like UnitedHealth (UNH).
• Implied IRR Calculation: At a forward P/E of 9.5x, Cigna’s implied earnings yield is approximately 10.5%. When combined with management’s long-term adjusted EPS growth target of 10% to 14%, the total implied IRR of share repurchases sits between 20.5% and 24.5%.
• The Hurdle Rate: For a large-scale acquisition to be "financially attractive" under current conditions, it would need to offer a risk-adjusted return exceeding this ~21%+ benchmark. Most large-scale M&A deals in the managed care space struggle to reach this threshold in the near term due to high integration costs and premium-to-market prices.

3. The M&A Pivot Threshold

Management has explicitly stated they will only pursue M&A that is "strategically aligned, financially attractive, and has a high probability to close." The "pivot" back to large-scale M&A (like Humana) likely depends on two primary variables:

Price-to-Earnings (P/E) Threshold The mathematical appeal of buybacks diminishes as Cigna’s stock price rises. If Cigna’s forward P/E multiple expands toward the 13x to 14x range, the earnings yield would drop to ~7.4%. At this level, the total IRR (Yield + Growth) falls toward 17%, making the potential synergies and long-term accretion of a strategic acquisition more competitive.

Target Valuation (The Humana Context) Humana (HUM) has recently faced a "perfect storm" of regulatory headwinds, including a significant drop in Medicare Advantage Star Ratings and rising medical utilization, which has compressed its valuation to multi-year lows. While Cigna officially distanced itself from merger talks in late 2024, the widening valuation gap between Cigna’s "undervalued" stock and Humana’s "distressed" valuation could eventually re-open the window if:

1. Cigna’s own multiple recovers (reducing buyback IRR).
2. Regulatory clarity regarding PBM (Pharmacy Benefit Manager) reform improves, reducing the "PBM discount" currently applied to Cigna’s stock.

4. Risks and Strategic Limitations

• Regulatory Scrutiny: The Federal Trade Commission (FTC) remains a significant barrier to mega-mergers in the healthcare sector. Cigna’s recent settlement regarding its pharmacy benefits model may provide a clearer path forward, but any attempt to integrate with a major insurer like Humana would face intense antitrust review.
• Opportunity Cost: Every dollar spent on buybacks is a dollar not spent on the Evernorth ecosystem (specialty pharmacy, behavioral health). If Cigna misses out on high-growth niche acquisitions while focusing on buybacks, it may risk long-term competitive positioning.
• Interest Rate Environment: With a debt-to-cap ratio of 43%, the cost of financing a multi-billion dollar acquisition remains sensitive to the prevailing rate environment, potentially further raising the required hurdle rate for M&A.